

Treatment Naïve, Chronic HCV


Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites

Muir AJ, et al. N Engl J Med. 2004;350:2265-71.

Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites Design

- **Study**
 - Prospective, multicenter, phase 3 trial
 - 16 centers in Southeastern United States
- **Subjects**
 - N = 200 adults with chronic HCV (100 blacks and 100 non-Hispanic whites)
 - Treatment naïve
 - HCV genotype (98% with genotype 1)
- **Regimens (Ribavirin Dosed by Weight)**
 - Peginterferon alfa-2b: 1.5 µg/kg 1x/week x 48 weeks +
Ribavirin 1000 mg/day for weeks 1-12, then 800 mg/day for weeks 13-48
- **Primary Endpoint (Sustained Virologic Response [SVR])**
 - SVR = Undetectable serum HCV RNA 24 weeks after 48-week treatments

Peginterferon alfa-2b + Ribavirin in Blacks and Non-Hispanic Whites Results



Drug Dosing


Peginterferon alfa-2b: 1.5 µg/kg 1x/week

Ribavirin (divided bid): 1000 mg/day x weeks 1-12, then 800 mg/day for weeks 13-48

Peginterferon alfa-2b + Ribavirin in Blacks and Non-Hispanic Whites

Results

Virologic Responses by Race



Peginterferon alfa-2b + Ribavirin in Blacks and Non-Hispanic Whites

Conclusions

Conclusions: “Black patients with chronic hepatitis C have a lower rate of response to treatment with peginterferon alfa-2b and ribavirin than non-Hispanic white patients, a difference that is not explained by differences in the viral genotype.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.